MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN
Year: 2016
Type: article
Abstract: // Xinying Xue 1, 2 , Yuxia Liu 3 , Yong Wang 1 , Mingming Meng 4 , Kaifei Wang 2 , Xuefeng Zang 5 , Sheng Zhao 6 , Xiaohua Sun 7 , Lei Cui 8 , Lei Pan 1 , Sanhong Liu 9 1 Department of Special Medical Treatment-Respiratory Disease, Beijing Shijitan Hospital, Capital Medical University, Beijing, China 2 Department of Respiratory Diseases of Chinese PLA General Hospital, Beijing, China 3 Department of Research, Peking Union Medical Collage Hospital, Beijing, China 4 Department of Gastroenterology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China 5 Department of Intensive Care Unit, Beijing Shijitan Hospital, Capital Medical University, Beijing, China 6 Department of Cardiology, Peking University Ninth School of Clinical Medicine, Beijing Shijitan Hospital, Beijing, China 7 Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicine, Shanghai, China 8 Department of Central Laboratory, Beijing Shijitan Hospital, Capital Medical University, Beijing, China 9 Shanghai Institute of Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China Correspondence to: Lei Pan, email: [email protected] Sanhong Liu, email: [email protected] Lei Cui, email: [email protected] Keywords: non-small cell lung carcinoma, miR-21, miR-155, SOCS1, SOCS6 Received: July 11, 2016 Accepted: October 25, 2016 Published: November 02, 2016 ABSTRACT Lung cancer remains the leading cause of cancer-associated death worldwide. MiR-21 and miR-155 are the most amplified miRNAs in non-small cell lung carcinoma (NSCLC), and are critical promoters of NSCLC progression. However, it remains unclear how miR-21 and miR-155 induce cancer progression, and whether these miRNAs share common targets, such as tumor suppressor genes required to prevent NSCLC. Here we report that miR-21 and miR-155 levels are elevated in NSCLC and are proportional to the progression of the disease. In addition, miR-21 and miR-155 share nearly 30% of their predicted target genes, including SOCS1 , SOCS6 , and PTEN , three tumor suppressor genes often silenced in NSCLC. Consequently, antagonizing miR-21, miR-155 or both potently inhibited tumor progression in xenografted animal models of NSCLC. Treatment with miR-21 and miR-155 inhibitors in combination was always more effective against NSCLC than treatment with a single inhibitor. Furthermore, levels of miR-21 and miR-155 expression correlated inversely with overall and disease-free survival of NSCLC patients. Our findings reveal that miR-21 and miR-155 promote the development of NSCLC, in part by downregulating SOCS1 , SOCS6 , and PTEN . Combined inhibition of miR-21 and miR-155 could improve the treatment of NSCLC.
Source: Oncotarget
Authors: Xinying Xue, Yuxia Liu, Yong Wang, Mingming Meng, Kaifei Wang, Xuefeng Zang, Sheng Zhao, Xiaohua Sun, Lei Cui, Lei Pan, Sanhong Liu
Institutions: Capital Medical University, Chinese PLA General Hospital, Beijing Shijitan Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking University, Shanghai Jiao Tong University, Chinese Academy of Sciences, Shanghai Institutes for Biological Sciences, ShanghaiTech University
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: diamond
OpenAlex ID: W2548791365
